首页 > 市场调查报告书 > 製药

糖尿病

市场调查报告书

商品编码

1768082

糖尿病设备和治疗市场（按类别、疾病类型和地区）

Diabetes Devices and Drugs Market, By Category (Diagnosis and Monitoring, Therapeutics), By Disease Type (Type 2 Diabetes, Type 1 Diabetes), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

出版日期: 2025年06月12日 | 出版商:

Coherent Market Insights | 英文 210 Pages | 商品交期: 2-3个工作天内

价格

简介目录

糖尿病设备和治疗市场预计在 2025 年达到 1,916.6 亿美元，预计到 2032 年将达到 3,734.9 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 10.0%。

报告范围		报告详细信息
基准年	2024	2025年的市场规模	1916.6亿美元
效能数据	2020-2024	预测期	2025-2032
预测期：2025-2032年	10.00%	2032年价值预测	3734.9亿美元

糖尿病设备和药物是指专门为帮助管理和治疗糖尿病（一种以高血糖为特征的慢性代谢性疾病）而设计的工具和药物。这些设备和药物在监测血糖值、注射胰岛素以及控製糖尿病相关症状和併发症发挥着至关重要的作用。血糖仪、连续血糖监测系统、胰岛素帮浦、胰岛素笔等都是帮助管理糖尿病的装置的例子。同时，药物包括胰岛素、Metformin、磺酰尿素类和Amylin。这些设备和药物对于糖尿病患者监测血糖值、注射胰岛素和有效管理病情至关重要，从而降低併发症风险并促进整体健康。

市场动态

全球糖尿病盛行率持续上升，主要原因是久坐不动的生活方式、不健康的饮食以及肥胖率上升等因素。糖尿病患者的激增带来了对有效监测和治疗糖尿病的设备和药物的巨大需求。在设备方面，持续血糖监测系统已广受欢迎。例如，2022年3月，全球领先的糖尿病患者即时持续血糖监测公司DexCom宣布，Dexcom G7持续血糖监测 (CGM) 系统已获得CE标誌（欧洲合格认证），可供2岁及以上糖尿病患者（包括孕妇）在欧洲使用。

糖尿病治疗市场也取得了显着发展。口服降血糖药物和胰岛素注射等传统疗法仍占市场主导地位。然而，人们越来越重视新型药物的开发，例如基于肠促胰岛素的促效剂、钠葡萄糖协同转运蛋白-2 (SGLT-2) 抑制剂以及（Glucagon-Like Peptide-1 ）GLP-1受体激动剂。这些创新药物疗效更佳，副作用更少，为患者带来了更多便利。

研究的主要特点

本报告对全球糖尿病设备和治疗市场进行了详细分析，并以 2024 年为基准年，展示了预测期 2025-2032 的市场规模和年复合成长率（CAGR%）。
它还强调了各个领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数，概述了全球糖尿病设备和药品市场的主要企业。
本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
本研究报告针对该产业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
相关人员可以透过分析全球糖尿病设备和治疗市场所使用的各种策略矩阵来促进决策。

介绍
北美洲
- 美国
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲国家
亚太地区
- 中国
- 印度
- 日本
- 东南亚国协
- 澳洲
- 韩国
- 其他亚太地区
中东
- 海湾合作委员会国家
- 以色列
- 其他中东地区
非洲
- 北非
- 中部非洲
- 南非

第七章竞争态势

公司简介
Abbott Laboratories
Bristol-Myers Squibb
DexCom, Inc.
Eli Lilly and Company
Companion Medical
GlaxoSmithKline plc
Glenmark Pharmaceuticals
Johnson & Johnson
Lupin Ltd.
F. Hoffmann-La Roche AG
DreaMed Diabetes
Hua Medicine
Sanofi

第 8 章章节

调查方法
关于出版商

简介目录

Product Code: CMI3857

Diabetes Devices And Drugs Market is estimated to be valued at USD 191.66 Bn in 2025 and is expected to reach USD 373.49 Bn by 2032, growing at a compound annual growth rate (CAGR) of 10.0% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 191.66 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	10.00%	2032 Value Projection:	USD 373.49 Bn

Diabetes devices and drugs refer to the tools and medications specifically designed to help individuals manage and treat diabetes, a chronic metabolic disorder characterized by high blood sugar levels. These devices and drugs play a crucial role in monitoring blood glucose levels, delivering insulin, and controlling the symptoms and complications associated with diabetes. Glucose meters, continuous glucose monitoring systems, insulin pumps, insulin pens, etc. are a few examples of devices that aid the management of diabetes. Whereas, drugs include insulin, metformin, sulfonylureas, amylin analogues, etc. These devices and drugs are essential for individuals with diabetes to monitor their blood sugar levels, administer insulin, and manage the condition effectively, thereby reducing the risk of complications and promoting overall well-being.

Market Dynamics

The global prevalence of diabetes has been rising steadily primarily driven by the factors such as sedentary lifestyles, unhealthy dietary habits, and increasing obesity rates. This surge in the diabetic population has created a substantial demand for effective devices and drugs to monitor and treat the condition. In terms of devices, continuous glucose monitoring systems have gained significant popularity. For instance, in March 2022, DexCom, Inc., the global leader in real-time continuous glucose monitoring for people with diabetes, announced that the Dexcom G7 Continuous Glucose Monitoring (CGM) System received CE Mark (Conformite Europeenne) for people with diabetes in Europe aged 2 and above, including pregnant women.

The market for diabetes drugs has also witnessed remarkable advancements. Traditional treatments, such as oral antidiabetic drugs and insulin injections, continue to dominate the market. However, there has been a growing emphasis on the development of novel drugs, including incretin-based therapies, Sodium-glucose Cotransporter-2 (SGLT-2) inhibitors, and (Glucagon-like Peptide-1) GLP-1 receptor agonists. These innovative medications offer improved efficacy and reduced side effects, and enhanced convenience for patients.

Key features of the study

This report provides an in-depth analysis of the global diabetes devices and drugs market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global diabetes devices and drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Abbott Laboratories, Bristol-Myers Squibb, DexCom, Inc., Eli Lilly and Company, Companion Medical, GlaxoSmithKline plc, Glenmark Pharmaceuticals, Johnson & Johnson, Lupin Ltd., F. Hoffmann-La Roche AG, DreaMed Diabetes, Hua Medicine and Sanofi.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global diabetes devices and drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diabetes devices and drugs market

Market Segmentation

Global Diabetes Devices and Drugs Market, By Category
- Diagnosis and Monitoring
- Blood Glucose Monitoring Devices
- Software Programs for Diabetes Monitoring
- Artificial Pancreas
- Other Testing Devices
- Therapeutics
- Insulin
- Insulin Delivery
- Oral Hypoglycemic Agents
- Cell Therapies
Global Diabetes Devices and Drugs Market, By Disease Type
- Type 2 Diabetes
- Type 1 Diabetes
Global Diabetes Devices and Drugs Market, By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
- Abbott Laboratories
- Bristol-Myers Squibb
- DexCom
- Eli Lilly and Company
- Companion Medical
- GlaxoSmithKline plc
- Glenmark Pharmaceuticals
- Johnson & Johnson
- Lupin Ltd.
- F.Hoffmann-La Roche AG
- DreaMed Diabetes
- Hua Medicine
- Sanofi

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Category
- Market Snapshot, By Disease Type
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis
Pipeline Analysis

4. Global Diabetes Devices and Drugs Market, By Category, 2020 - 2032, (US$ Billion)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Diagnosis and Monitoring
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
- Segment Trends
  - Blood Glucose Monitoring Devices
  - Software Programs for Diabetes Monitoring
  - Artificial Pancreas
  - Other Testing Devices
Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
- Segment Trends
  - Insulin
  - Insulin Delivery
  - Oral Hypoglycemic Agents
  - Cell Therapies

5. Global Diabetes Devices and Drugs Market, By Disease Type, 2020 - 2032 (US$ Billion)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Type 2 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Billion)
Type 1 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Billion)

6. Global Diabetes Devices and Drugs Market, By Region, 2020 - 2032, (US$ Billion)

Overview
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2032
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Category, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Category, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Category, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Category, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Category, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Category, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Company Profiles
Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
DexCom, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Companion Medical
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Glenmark Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Lupin Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
F. Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
DreaMed Diabetes
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Hua Medicine
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies

8. Section

Research Methodology
About Us

02-2729-4219

+886-2-2729-4219

License/价格

糖尿病设备和治疗市场（按类别、疾病类型和地区）

Diabetes Devices and Drugs Market, By Category (Diagnosis and Monitoring, Therapeutics), By Disease Type (Type 2 Diabetes, Type 1 Diabetes), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

市场动态